



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



RP 6306

Item No. 41732

CAS Registry No.: 2719793-90-3
Formal Name: (1S)-2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

Synonyms: Lunresertib, (S)-RP 6306

MF: C₁₈H₂₀N₄O₂


FW: 324.4

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RP 6306 is supplied as a solid. A stock solution may be made by dissolving the RP 6306 in the solvent of choice, which should be purged with an inert gas. RP 6306 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

RP 6306 is an inhibitor of membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (Myt1 kinase), also known as PKMYT1 (IC₅₀ = 0.002 nM in a bioluminescence resonance energy transfer (BRET) assay).¹ It is greater than 29-fold selective for Myt1 kinase over eight other kinases in BRET assays at 1.2 μM. RP 6306 (500 nM) increases the levels of DNA-associated γ histone H2AX (γH2AX), a marker of DNA damage, in hTERT FT 282 fallopian tube cells.² It induces cell cycle arrest at the S phase in hTERT FT 282 cells. Dietary administration of RP 6306 (15, 50, or 300 ppm) reduces tumor volume in an OVCAR-3 ovarian cancer mouse xenograft model.¹

References

1. Szychowski, J., Papp, R., Dietrich, E., *et al.* Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306. *J. Med. Chem.* **65**(15), 10251-10284 (2022).
2. Gallo, D., Young, J.T.F., Fourtounis, J., *et al.* CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. *Nature* **604**(7907), 749-756 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/14/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM